Novartis shares plunge 10% after experimental neuromuscular drug fails late-stage trial
Swiss pharmaceutical giant Novartis saw its stock drop as much as 10% following the failure of an experimental neuromuscular treatment in a late-stage clinical trial. The setback comes just days after another high-profile trial failure in heart disease, marking the company's third recent drug development disappointment.
